Canaloplasty ab interno (AbiC) – 2-Year-Results of a Novel Minimally Invasive Glaucoma Surgery (MIGS) Technique

Kazerounian, Sara; Zimbelmann, Michael; Lörtscher, Martin; Hommayda, Sufian; Tsirkinidou, Irene; Müller, Maya

doi:10.1055/a-1250-8431

Cited by 17 publications

(19 citation statements)

References 18 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall reduction in IOP in the entire cohort was 29.0% at 12 months (from 22.5 ± 5.3 mmHg to 15.0 ± 3.6 mmHg). Similar IOP changes have been described for ABeC [ 17 , 18 ] and ABiC [ 21 , 23 , 24 , 25 ] in previous studies. Brusini [ 19 ] reported a more favorable reduction in IOP from 29.4 ± 7.9 preoperatively to 16.8 ± 4.2 mmHg at 12 months probably due to the higher IOP level at baseline compared with the other studies.…”

Section: Discussionsupporting

confidence: 88%

“…The higher rate of hyphema could be due to the fact that the surgeons used the OMNI system to perform canaloplasty combined with trabeculotomy. The rates of hyphema for the ABiC procedure reported in literature ranges from 0% to 20% [ 21 , 23 , 24 , 25 ]. The higher rate of 20% was found in the study by Kazerounian [ 25 ], which refers to mild hyphema cases with no late sequelae.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

360° Ab-Interno Schlemm’s Canal Viscodilation with OMNI Viscosurgical Systems for Open-Angle Glaucoma—Midterm Results

Toneatto

Zeppieri

Papa

et al. 2022

JCM

View full text Add to dashboard Cite

Purpose: To evaluate the effectiveness of ab-interno microcatheterization and 360° viscodilation of Schlemm’s canal (SC) performed with OMNI viscosurgical system in open angle glaucoma (OAG) together or not with phacoemulsification. Setting: Two surgical sites. Design: Retrospective, observational. Methods: Eighty eyes from 73 patients with mild to moderate OAG underwent ab- interno SC viscodilation performed with OMNI system. Fifty eyes (Group 1) underwent only SC viscodilation, while 30 eyes (Group 2) underwent glaucoma surgery + cataract extraction. Primary success endpoint at 12 months was an intraocular pressure (IOP) reduction higher than 25% from baseline with an absolute value of 18 mmHg or lower, either on the same number or fewer ocular hypotensive medications, without further interventions. Secondary effectiveness endpoints included mean IOP, number of medications and comparison of outcomes between groups. Safety endpoints consisted of best-corrected visual acuity (BCVA), adverse events (AEs), and subsequent surgical procedures. Results: Primary success was achieved in 40.0% and 67.9% in Groups 1 and 2, respectively. Mean IOP at 12-month follow-up showed a significant reduction in both groups (from 23.0 to 15.6 mmHg, p < 0.001, and from 21.5 to 14.1, p < 0.001, in Groups 1 and 2, respectively). Mean medication number decreased in both groups (from 3.0 to 2.0, p < 0.001 and from 3.4 to 1.9, p < 0.001, in Groups 1 and 2, respectively). AEs included hyphema (2 eyes), mild hypotony (4 eyes), IOP spikes one month after surgery (1 eye). Twelve eyes (15.0%) required subsequent surgical procedures. No BCVA reduction was observed. Conclusions: Viscodilation of SC using OMNI viscosurgical systems is safe and relatively effective in reducing IOP in adult patients with OAG.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

360° Ab-Interno Schlemm’s Canal Viscodilation with OMNI Viscosurgical Systems for Open-Angle Glaucoma—Midterm Results

Toneatto

Zeppieri

Papa

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Patient reliance on medications was also reduced, with the mean number of medications falling from 1.69 at baseline (n=23) to 0.21 at the last follow-up visit (n=11). A 2020 study by Kazerounian et al 20 demonstrated a reduction in mean IOP of 32.5% from 20.24 mmHg ± 5.92 (n = 25) at baseline to 13.67 mmHg ± 2.15 (n = 21, P <0.001) at 24 months following iTrack ab-interno canaloplasty. Medication reduction was also significant, falling from 1.92 ± 1.04 at baseline to 0.05 ± 0.23 at 24 months.…”

Section: Discussionmentioning

confidence: 95%

“…The 24-month results of the present study are in line with previously reported 12-month results. 10 , 19 , 20 A 2018 study by Gallardo et al demonstrated a mean IOP reduction of 32.8% ( P < 0.001) in standalone cases (n = 41) and 31.7% ( P < 0.001) in combined cataract surgery cases (n = 34) respectively, at 12 months. In a 2018 study by Koerber et al, 19 mean IOP reduced from 18.8 ± 5.63 at baseline (n=23) to 14.73 ± 2.97 mmHg at 12 months (n=11).…”

Section: Discussionmentioning

confidence: 98%

24-Month Efficacy of Viscodilation of Schlemm’s Canal and the Distal Outflow System with iTrack Ab-Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma

Gallardo¹

2021

OPTH

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the 24-month efficacy of viscodilation of Schlemm’s canal and the distal outflow system with iTrack ab-interno canaloplasty in reducing intraocular pressure (IOP) and antiglaucoma medication use in patients with primary open-angle glaucoma (POAG). Patients and Methods This retrospective, comparative, and consecutive case series assessed the 24-month outcomes of iTrack as a standalone procedure (iTrack-alone) or in conjunction with cataract surgery (iTrack+phaco), in cases of mild, moderate or severe POAG. Data were collected at baseline and the 12- and 24-month follow-up visits. Results The study included 53 patients (60 eyes) with a mean age of 73.6±9 years. For all eyes, a significant reduction in mean IOP was seen at 12 and 24 months, reducing from 20±4.9 mmHg at baseline to 13.6±1.9 mmHg and 13.5±2.6 mmHg, respectively ( P <0.001). The reduction in medications was also significant, reducing to 1.12±1.09 and 1.7±1.29 medications at 12 months and 24 months, respectively, from a baseline of 2.77±0.91 ( P <0.001). Similar results were achieved whether iTrack was performed as a standalone procedure, or in conjunction with cataract surgery. While the iTrack-alone group started with a higher IOP at baseline, both groups experienced similar and stable IOP reduction of more than 30% from baseline. The reduction in medication use was also significant in both groups, decreasing from 3±0.7 for iTrack-alone and 2.5±1.1 for iTrack+phaco at baseline to 2.1±1.3 and 1.3±1.2 at 24 months, respectively ( P <0.001). The 24-month efficacy outcomes were similar in cases of mild–moderate versus severe glaucoma. No serious adverse events were recorded. Conclusion Twenty-four-month follow-up data demonstrate that iTrack ab-interno canaloplasty can effectively reduce IOP and medication dependence, with a good safety profile. These results also demonstrate that iTrack can be effectively performed as a standalone procedure or in combination with cataract surgery, and in all grades of glaucoma severity.

show abstract

“…Clinical evidence indicates that ab-interno canaloplasty is safe and effective in lowering IOP and reducing medication burden in mild-moderate POAG. 22 , 25 , 26 A consecutive case series by Gallardo et al 25 demonstrated the clinical efficacy and safety of iTrack ab-interno canaloplasty over a 12-month period. Overall, 84.9% of eyes experienced a reduction in IOP which was greater than 20%.…”

Section: Discussionmentioning

confidence: 99%

Long-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery

Khaimi

2021

Ophthalmol Eye Dis

View full text Add to dashboard Cite

Purpose: To evaluate the long-term effectiveness of iTrack (Nova Eye Medical, Fremont, USA) ab-interno canaloplasty performed as a standalone procedure, or combined with cataract surgery, in reducing antiglaucoma medication dependence and maintaining intraocular pressure within target range in patients with controlled primary open-angle glaucoma. Methods: This is a retrospective, single-center, case series study of patients who underwent iTrack ab-interno canaloplasty as a standalone procedure ( n = 34) or in combination with cataract surgery ( n = 11). Eyes with controlled mild or moderate glaucoma (intraocular pressure ⩽17 mmHg) were included; those with prior glaucoma surgeries were excluded. The primary outcome was the mean reduction in glaucoma medication and the secondary outcome was the maintenance of controlled intraocular pressure postoperatively. Results: A total of 35 patients (45 eyes) with a mean age of 73 ± 9.7 years were included in the study. For all eyes, a significant decrease (61%) in the mean number of medications was seen at 36 months (1.89 ± 0.93 versus 0.60 ± 0.82; p < 0.001), with 56% (14/25) of eyes medication free. No significant difference was observed in the reduction of medication use whether iTrack was performed with or without cataract surgery at 12 and 36 months. Mean baseline intraocular pressure of 14.42 ± 2.2 mmHg for all eyes was maintained at the 12-, 24-, and 36-month follow-up visits (14.6 ± 3.65, 15.06 ± 2.26, and 14.19 ± 2.91, respectively), with no significant difference between the two groups ( p = 0.08). Conclusion: The iTrack ab-interno canaloplasty significantly reduced medication dependency and maintained intraocular pressure within target range in patients with controlled mild or moderate primary open-angle glaucoma, while showing a good safety profile, both as a standalone procedure or in combination with cataract surgery.

show abstract

Canaloplasty ab interno (AbiC) – 2-Year-Results of a Novel Minimally Invasive Glaucoma Surgery (MIGS) Technique

Cited by 17 publications

References 18 publications

360° Ab-Interno Schlemm’s Canal Viscodilation with OMNI Viscosurgical Systems for Open-Angle Glaucoma—Midterm Results

360° Ab-Interno Schlemm’s Canal Viscodilation with OMNI Viscosurgical Systems for Open-Angle Glaucoma—Midterm Results

24-Month Efficacy of Viscodilation of Schlemm’s Canal and the Distal Outflow System with iTrack Ab-Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma

Long-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery

Contact Info

Product

Resources

About